SELLAS Life Sciences Group, Inc. (SLS) financials

SELLAS Life Sciences Group, Inc. (SLS) revenue, EBIT and EBITDA, earnings per share, free cash flow, margins, debt and shareholders equity — annual and quarterly history, charted from SEC filings. No account needed.

In fiscal 2023, SELLAS Life Sciences Group, Inc. reported revenue of $0, down 100.0% year over year, net income of -$37M and diluted EPS of -$1.34.

Revenue (fiscal 2023)

$0

Revenue growth (fiscal 2023)

-100.0%

Net income (fiscal 2023)

-$37M

Diluted EPS (fiscal 2023)

-$1.34

SELLAS Life Sciences Group, Inc. files with the U.S. Securities and Exchange Commission under CIK 0001390478, classified as Pharmaceutical Preparations.

Explore annual and quarterly revenue, earnings, cash flow, margins, debt and equity from SEC filings.